Today's Rundown 5 months after launch, Allogene guns for $100M IPO Allergan defuses Botox threat with $195M Bonti buy José Baselga resigns from MSK over disclosure controversy Supernus adds epilepsy candidate with $185M Biscayne buy Bone Therapeutics’ cell therapy hits goal in phase 1/2a, but manufacturing changes slow progress Cochlear neuron discovery could yield new treatments for hearing loss FDA sets back review date of Acorda’s levodopa inhaler for Parkinson’s disease EuroBiotech Report—Gilead-Galapagos, Boehringer, Crescendo and Medivir hire CMOs and Pfizer-Cytoo FiercePharmaAsia—Takeda’s internal discord and U.S. HQ move; Sanofi reorg and more Chutes & Ladders—Ex-Gilead CMO Andrew Cheng to lead Akero Featured Story | | | Friday, September 14, 2018 Arie Belldegrun and David Chang launched Allogene earlier this year with $300 million and a clutch of allogeneic CAR-T assets. Now, five months, a new CFO and another $120 million later, the company has filed to raise up to $100 million in its IPO. |
|
|
| This week's sponsor is Synteract, Inc. | | | |
Top Stories Friday, September 14, 2018 Allergan has agreed to pay $195 million to acquire Bonti, a startup founded by former Allergan executives focused on creating a new botulinum neurotoxin. Friday, September 14, 2018 José Baselga, M.D., Ph.D., has resigned from Memorial Sloan Kettering (MSK) Cancer Center in the wake of a report about his failure to disclose his financial ties to drug developers in research papers. Baselga framed his resignation as an attempt to stop the news from becoming a distraction for MSK. Friday, September 14, 2018 CNS drug specialist Supernus makes a return to epilepsy R&D, buying the developer of a traditional Chinese medicine-derived drug for $15 million upfront. Friday, September 14, 2018 A phase 1/2a trial of Bone Therapeutics’ cell therapy treatment for delayed-union fractures has met its primary endpoint. Bone wants to move the therapy, ALLOB, into phase 2b on the strength of the data, but that plan is on hold as it adopts an industrialized manufacturing process. Thursday, September 13, 2018 Scientists from Karolinska Institutet in Sweden have discovered that type 1 neurons—a heterogeneous group—actually comprise three distinct subtypes of neurons. The discovery could support the development of new treatments for hearing loss. Friday, September 14, 2018 Acorda Therapeutics’ share price took a beating this week, losing about a third of its value after a one-two punch from the courts and the FDA, which extended its review of its drug-device combination treatment for Parkinson’s disease by three months. Friday, September 14, 2018 In this week's EuroBiotech Report, Gilead, Galapagos post filgotinib data, Boehringer buys oncolytic virus startup, Crescendo names CMO and more. Friday, September 14, 2018 A Takeda founding family member has gone public with his opposition to the Shire purchase, but that doesn't stop the company from planning for a successful deal as it moves its U.S. headquarters closer to Shire's operations; Sanofi is creating two units, one of which will have a renewed focus on China. Friday, September 14, 2018 Former Gilead CMO Andrew Cheng to lead Akero Therapeutics; Sanofi trades executives with Bayer in unit restructuring; Crescendo names ex-Roche leader as CMO; and Medivir adds Darzalex R&D experience to its clinical team with new CMO. Those moves plus more hirings, firings and retirings throughout the industry. Resources Sponsored by: Veeva A top 20 pharma and growing biotech re-engineer regulatory processes. Sponsored by: Sciformix Are automation, big data and artificial intelligence (AI) a key part of your company’s pharmacovigilance strategy? Read this whitepaper to know what they should be! Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. Sponsored by: Patheon, part of Thermo Fisher Scientific When developing a parenteral, pharmaceutical scientists are faced with a variety of choices – choices that can be conflicting or present differing advantages. Sponsored by: Baxter Baxter BioPharma Solutions’ whitepaper offers a method to address the challenges of tech transfer for lyophilized products from lab-scale to commercial-scale. Sponsored by: Catalent In this case study, an unknown leachable species was detected by GC-MS analysis of an alkaline drug product (pH approximately 10.5) that was packaged in a novel self- contained plastic Blow Fill Seal (BFS) vial. Sponsored by: Blue Matter A whitepaper outlining the key commercial challenges facing rare disease products, and how biopharmaceutical companies can overcome them. Sponsored by: AWS and Tableau Inova is using the capabilities of Tableau on AWS to identify biomarkers for personalized treatment intended to improve health outcomes for children. Sponsored by: Catalent Catalent provides world class stability services to ease your critical path to success. Sponsored by: AWS and Reltio Reltio and IQVIA provide holistic data management solutions for traditional pharma, emerging biotech, and consumer health companies, on AWS. Presented by: AWS and Druva Life Sciences organizations are embracing cloud-based Master Data Management (MDM) to modernize the organization of critical data. Sponsored by: Health Strategies Group The window of market exclusivity continues to narrow dramatically in the global marketplace. Given this demanding environment, your global market access team faces increasing urgency to get the value proposition right at the time of launch. Drug Approval, Manufacturing Quality & Regulation 2018 | Online Drug Development Boot Camp® 2018 – Registration closes 30 October - Register Now! November 14-15, 2018 | Boston, MA | Registration closes on the 30 of October 2018 due to the need for participants to complete pre-Boot Camp preparations. Register now and start preparing for this intensive training in drug development. 2018 Latin America Healthcare Compliance Certification Program September 24-27, 2018 | Sao Paulo, Brazil FierceBiotech 3rd Drug Development Forum October 1–3, 2018 | Hilton Boston Logan Airport Hotel | Boston, MA Compliance Certification Program at Seton Hall Law October 8-11, 2018 | Newark, NJ BioImmersion: Biotech for the Non-Scientist October 16-18, 2018 | Chicago, IL Fierce Innovation Awards: Life Sciences Edition 2018 FierceBiotech Executive Summit: London October 30, 2018 | Royal Society of Medicine Understanding Commercialization Within Biopharma Nov 7-8, 2018 | Boston, MA Drug Development Boot Camp® 2018 – Register Now! November 14-15, 2018 | Boston, MA | Register now and start your pre-Boot Camp preparation Drug Development Immersion December 5-6, 2018 | San Diego, CA Understanding Drug Pricing and Reimbursement December 12, 2018 | Boston, MA | 